KCT0012405进行中（未招募）2 期
Everolimus in Liver Transplant Recipients with 18F-FDG-avid Hepatocellular Carcinoma on PET/CT (EVEREST-LT): A Phase 2, Multicenter, Single Arm Trial
适应症
试验速览
- 阶段
- 2 期
- 状态
- 进行中（未招募）
- 入组人数
- 59
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 主要目的
- Treatment
入排标准
- 年龄范围
- 19(Year) 至 No Limit（—）
- 性别
- All
入选标准
- •Patients aged 19 and over, but under 80
- •Patients who are able to voluntarily sign a written informed consent form
- •Patients diagnosed with hepatocellular carcinoma (HCC) according to the American Association for the Study of Liver Diseases (AASLD) or European Association for the Study of the Liver (EASL) guidelines, and who are candidates for liver transplantation (from a deceased or living donor)
- •Patients with confirmed 18F-FDG-avid HCC (Tumor SUVmax/Liver SUVmax >= 1.15) at least once on 18F-FDG PET/CT within 3 months prior to the scheduled liver transplantation date
- •Patients with confirmed viable HCC (LR-5 or LR-TR-V lesion) on liver CT or MRI within 1 month prior to the scheduled liver transplantation date
- •Patients who are capable of understanding and following instructions and who can participate for the entire duration of the study schedule
排除标准
- •Patients with confirmed macrovascular tumor thrombosis or extrahepatic metastasis at any time since the diagnosis of hepatocellular carcinoma (HCC) (including cases confirmed by explant histopathology after liver transplantation)
- •Patients diagnosed with extrahepatic malignancy within 5 years prior to study participation (except for non-melanoma skin cancer [basal cell carcinoma, squamous cell carcinoma] and carcinoma in situ [e.g., cervical carcinoma in situ, ductal carcinoma in situ, etc.] that have been completely cured with appropriate treatment and show no evidence of current recurrence)
- •Patients scheduled for ABO-incompatible liver transplantation
- •Patients with no viable HCC confirmed on explant histopathology after liver transplantation, or those with combined HCC/cholangiocarcinoma (CCA)
- •Patients with confirmed recurrence of HCC prior to the initiation of everolimus
- •Patients with a history of hypersensitivity or allergic reactions to everolimus, other mTOR inhibitors, or lactose
- •Patients requiring continuous administration of potent CYP3A4 inhibitors or inducersPatients who received systemic chemotherapy for HCC prior to liver transplantation
- •Patients with uncontrolled comorbidities, such as diabetes mellitus, dyslipidemia, or hypertension, despite appropriate medical therapy
- •Recipients of organ transplants other than the liver
- •Pregnant or lactating women
- •Patients with an ECOG performance status of 2 or higher at the time of everolimus initiation
- •Patients with a urine protein-to-creatinine ratio (UPCR) >=1.0 mg/mg on urinalysis, or an estimated glomerular filtration rate (eGFR) < 30 mL/min/1.73m2 (MDRD equation)
- •Patients with severe cardiovascular or cerebrovascular disease, or those deemed unsuitable for study participation by the principal investigator (or sub-investigator)
研究者
相似试验
已完成
不适用
PREPARE-iVACHerpes Zoster2023-503894-39-00Universitair Medisch Centrum Groningen, Universitair Medisch Centrum Groningen110
尚未招募
4 期
Use of platelet-improving medicine Romiplostim in Liver Transplant PatientCTRI/2024/04/066269Amrita School of Pharmacy24
尚未招募
4 期
Fibrinogen in Liver TransplantNCT07265843Trauma Hemostatis and Oxygenation Research (THOR) Network60
尚未招募
不适用
Study on the Combined Treatment of Hepatocellular Carcinoma With Envafolimab, Suvemcitug and HAIC ConversionPotentially Resectable Hepatocellular CarcinomaNCT07738055Tianjin Medical University Cancer Institute and Hospital35
Enrolling By Invitation
不适用
Immunosuppressant Withdrawal Based on Parenchymal Chimerism in the Liver TransplantationLiver TransplantationLiver Transplantation in Long-termNCT07735650Chang Gung Memorial Hospital60